Prior authorisation: what the criteria usually require — a second dataset posts 61–75

This follows post #58 rather than contradicting it.

Appeals process: unemotional prose, the criterion quoted verbatim, evidence mapped to it point by point, dates, and nothing else. Describing how the decision affected you is understandable but does not move the needle in appeals.

I read post #60 twice before replying, because I had assumed the opposite.

Documentation your clinician can provide: letters from clinicians describing why standard treatments have failed or are contraindicated are often exactly what an appeals process needs.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and appeals based on the covered indication work better.

Picking up post #62: that is the part I would want checked first.

Documentation your clinician can provide: letters from clinicians describing why standard treatments have failed or are contraindicated are often exactly what an appeals process needs.

Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and appeals based on the covered indication work better.

Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves surprise at the pharmacy.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.

Worth separating two things that post #67 runs together.

Appeals process: unemotional prose, the criterion quoted verbatim, evidence mapped to it point by point, dates, and nothing else. Describing how the decision affected you is understandable but does not move the needle in appeals.

Denial letters: the stated reason tells you exactly what to submit next. A denial is not final; it is a specification for an appeal. Reading the reason carefully and responding point-by-point to it works better than general appeals.

Tier placement and step therapy: some formularies place a medication on a higher tier or require you to fail cheaper alternatives before approving the one you want. Understanding the requirements before treatment starts matters.

Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.